MedTrace Logo

Quadratus Lumborum Block for Percutaneous Nephrostomy

NCT02121951 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2018-04-10

No results posted yet for this study

Summary

Percutaneous nephrostomy (PCN) is one of the interventions in the radiology department in which pain control is necessary. Quadratus Lumborum (QL) block will be tried to limit the use of systemic analgesics and its accompanying untoward effects in those frail patients requiring PCN that is performed in the prone position.

Conditions

  • Nephrostomy; Complications
  • Upper Urinary Tract Dilatation and Obstruction
  • Regional Anesthesia Morbidity
  • Adverse Anesthesia Outcome

Interventions

PROCEDURE

Local Anesthetic infiltration

Lignocaine infiltration through the nephrostomy track

PROCEDURE

Quadratus Lumborum block

A linear 12-MHz ultrasound probe will be placed in the anterior axillary line to visualize the typical triple abdominal layers. Then, the probe will be placed in the midaxillary line and at this point the layers of abdominal layers starte to taper. The probe will be placed in the posterior axillary line, sonoanatomy will show first the transversus abdominis disappearing then the internal oblique and external oblique forming aponeurosis and appearance of QL will be noticed. At the posterior border of the quadratus lumborum muscle and outside the fascia, Touhe needle will be inserted in plane and confirmed its position by injecting saline. Under ultrasound (US) guidance, local anesthetic mixure will be deposited separating the fascia

DRUG

MAC

Incremental doses are given to the targed sedation and analgesia

Sponsors & Collaborators

  • National Cancer Institute, Egypt

    lead OTHER

Principal Investigators

  • Dina N Abbas, M D · National Cancer Institute, Egypt

  • Ghada M Bashandy, MD · National Cancer Institute, Egypt

  • Wael Darwish, M D · National Cancer Institute, Egypt

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2014-05-31
Completion
2014-08-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02121951 on ClinicalTrials.gov